Business Context and Reporting Period
Company: Xtant Medical Holdings, Inc. (XTNT)
Filing Type: Form 8-K (Current Report)
Date of Report: August 12, 2025
Reporting Period: The filing announces financial results for the three and six months ended June 30, 2025 (Second Quarter 2025).
Key Financial Metrics
The provided text serves as a cover document referencing a press release (Exhibit 99.1) and an investor presentation (Exhibit 99.2) for detailed figures. Consequently, specific numerical values for the following metrics are not present in the filing text:
- Revenue: Not provided in text.
- Profit/Loss: Not provided in text.
- Cash Flow: Not provided in text.
- Margins: Not provided in text.
- Debt and Liquidity: Not provided in text.
Non-GAAP Measures: The Company utilizes "non-GAAP adjusted EBITDA" to assess core operational performance. This metric adjusts net income to exclude separation-related expenses, non-cash compensation, divestiture/acquisition-related expenses, acquisition-related fair value adjustments, and unrealized foreign currency translation gains or losses.
Material Changes and Strategic Context
While specific comparative financial data is absent from this text, the filing highlights the following material operational context:
- Divestiture Activity: The Company is in the process of divesting its non-core Coflex/CoFix spinal implants and international business.
- Expense Classification: Expenses related to this divestiture, as well as acquisition integration costs, are excluded from non-GAAP adjusted EBITDA as they are not considered reflective of ongoing operating results.
Guidance, Outlook, and Risks
Management Commentary: Management utilizes non-GAAP adjusted EBITDA to facilitate internal comparisons, budgeting, and resource allocation for sales, marketing, and R&D. They believe this measure removes the impact of unpredictable charges and non-cash items to better reflect core profitability.
Forward-Looking Information: The Company has released an Investor Presentation (Exhibit 99.2) intended for use at investor conferences. The filing explicitly states that the Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation, though it may do so at management's discretion.
Risks and Contingencies: The text notes standard limitations regarding non-GAAP financial measures, stating they are not in accordance with GAAP and may differ from measures used by other companies, limiting comparability.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and cash flow figures for Q2 2025.
- Examine the reconciliation table in the press release to understand the magnitude of adjustments made to reach non-GAAP adjusted EBITDA.
- Consult Exhibit 99.2 (Investor Presentation) for updated guidance, outlook, and strategic details regarding the Coflex/CoFix divestiture.
- Verify the status of the pending divestiture of non-core spinal implants and international business to assess future revenue streams.